Vern C. Juel, M.D. – Myasthenic Syndromes, Congenital

Access Program Information

This is a continuing project to provide 3,4 diaminopyridine (DAP) under a treatment-use IND
to patients with Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndrome
(CMS).